Compare DexCom, Inc. (DXCM) vs Lululemon Athletica Inc (LULU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Lululemon Athletica Inc — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Lululemon Athletica Inc trades at $94.4 (market cap $10.27B). The key difference: DexCom, Inc. is far larger — about 3.1× Lululemon Athletica Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Lululemon Athletica Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Lululemon Athletica Inc for 105 Days on average.
| DXCM | LULU | |
|---|---|---|
Market Cap | $31.86B | $10.27B |
Volume | 3,607,070 | 4,392,324 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $215.88 |
52-Week Low | $54.84 | $91.88 |
Typical Hold Time | 62 Days | 105 Days |
Enterprise Value | $31.32B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
Lululemon stock trades at $94.5, down 54% year-to-date and near its 52-week low, reflecting a bearish technical trend. Despite strong profitability with a 12.78% net income margin and a low P/E of 7.63, the stock faces headwinds from recent revenue declines and multiple securities fraud investigations. Earnings have beaten estimates in recent quarters, but negative sentiment and governance concerns weigh on investor confidence.
The outlook remains cautious; the stock's deep discount to historical valuations presents a potential opportunity, but risks from legal probes, competitive pressures, and weak growth visibility suggest limited near-term upside. Analyst consensus is mixed with a $97.67 price target, indicating modest potential from current levels amid high uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →
